Pure Global: Brazil's SaMD Shift - Unpacking ANVISA's Hidden Hurdles for Foreign Tech

Impossibile aggiungere al carrello

Puoi avere soltanto 50 titoli nel carrello per il checkout.

Riprova più tardi

Rimozione dalla Lista desideri non riuscita.

Riprova più tardi

Non è stato possibile aggiungere il titolo alla Libreria

Per favore riprova

Non è stato possibile seguire il Podcast

Per favore riprova

Esecuzione del comando Non seguire più non riuscita

Pure Global: Brazil's SaMD Shift - Unpacking ANVISA's Hidden Hurdles for Foreign Tech

Ascolta gratuitamente

Vedi i dettagli del titolo

3 mesi a soli 0,99 €/mese

Dopo 3 mesi, 9,99 €/mese. Si applicano termini e condizioni.

A proposito di questo titolo

In this episode of LATAM MedTech Insights, we dissect the critical regulatory updates from Brazil's ANVISA that are reshaping the landscape for Software as a Medical Device (SaMD). This is not a minor tweak; it's a fundamental shift demanding that foreign manufacturers, especially in the AI and digital health sectors, rethink their entire market entry strategy. We explore the immediate implications of these new clarifications, focusing on the heightened demands for localized clinical data and the stringent requirements of Brazil's data privacy laws. This episode provides essential insights for any company looking to stay compliant and competitive in Latin America's largest and most complex market. **A Real-World Challenge:** Imagine you are a US-based scale-up with a revolutionary AI diagnostic tool, poised to enter the Brazilian market. Suddenly, you discover your extensive US and EU clinical data is deemed insufficient by ANVISA. You are now facing an unexpected, year-long delay to conduct local studies, jeopardizing your funding and first-mover advantage. How do you navigate this without derailing your entire LATAM launch? **Key Takeaways From This Episode:** * What specific clinical evidence is ANVISA now demanding for foreign SaMD? * How does Brazil's data privacy law (LGPD) impact your software's architecture? * Why is the risk classification for your AI-driven device more complex than you think? * What is the biggest mistake companies make when interpreting these new guidelines? * Could these stricter regulations hide unforeseen opportunities for well-prepared companies? * How can you leverage regulatory reliance pathways to potentially streamline this process? * What are the three essential questions to ask your local regulatory partner today? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI and data tools to streamline global market access. We help you turn regulatory hurdles into market opportunities. To learn more about navigating Brazil's evolving landscape or expanding into over 30 other global markets, contact us at info@pureglobal.com or visit https://pureglobal.com/.

Ancora nessuna recensione